REG - Diaceutics PLC - Purchase of Shares and PDMR Shareholding

DiaceuticsAnnouncement

31/01/2025 09:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250131:nRSe4627Va&default-theme=true

RNS Number : 4627V  Diaceutics PLC  31 January 2025

 

 

 

Diaceutics PLC

 

Purchase of Shares and PDMR Shareholding

 

New York, Belfast and London, 31 January 2025 - Diaceutics PLC (AIM: DXRX), a
leading technology and solutions provider to the pharma and biotech industry,
announces that on 30 January 2025, Graham Paterson, the Senior Independent
Non-Executive Director of Diaceutics PLC, purchased 11,643 ordinary shares of
£0.002 in the capital of the Company ("Ordinary Shares") at a price of 137.5
pence per Ordinary Share. As a result of the purchase, Graham's shareholding
is 85,141 Ordinary Shares, representing approximately 0.10% of the Company's
issued share capital.

 

 

Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer           Tel: +44 (0)28 9040 6500
 Nick Roberts, Chief Financial Officer           investorrelations@diaceutics.com

 Canaccord Genuity Limited (Nomad & Broker)      Tel: +44 (0)20 7253 8000
 Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome. We provide the world's leading pharma and biotech companies
with an end-to-end commercialisation solution for precision medicines through
data analytics, scientific and advisory services enabled by our platform DXRX
- The Diagnostics Network ®.

 

 

 

 

 

 

 

 

 

 

 

 

 

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
 596/2014
 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a.  Name                                                         Graham Paterson
 2   Reason for notification
 a.  Position/Status                                              Non-Executive Director
 b.  Initial notification/                                        Initial

     Amendment
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a.  Name                                                         Diaceutics PLC
 b.  LEI                                                          213800VEWQBB39ZB8J81
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a.  Description of the financial instrument, type of instrument  Ordinary shares of £0.002 each

Identification Code

                                                                  ISIN:  GB00BJQTGV64
 b.  Nature of the transaction                                    Purchase
 c.  Price(s) and volume(s)                                                    Share purchase:
                                                                               Price(s)     Volume(s)
     137.5 p                                                                   11,643

 e.  Date of the transaction                                      30 January 2025
 f.  Place of the transaction                                     AIM Market of the London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFIFLALLILVIE